Pramlintide (Symlin)

What is Pramlintide (Symlin)?#

Pramlintide (marketed as Symlin) is a synthetic analog of human amylin, a 37-amino acid peptide hormone that is co-secreted with insulin from pancreatic beta cells in response to food intake. It was FDA-approved in March 2005 as an adjunct to mealtime insulin in patients with type 1 or type 2 diabetes who have not achieved adequate glycemic control with insulin therapy alone.

In both type 1 and type 2 diabetes, amylin secretion is deficient or absent. Pramlintide replaces this missing hormone, providing complementary glucose-lowering effects that insulin alone cannot achieve: slowing gastric emptying, suppressing inappropriate postprandial glucagon secretion, and promoting satiety.

Pramlintide differs from native amylin by three proline substitutions at positions 25, 28, and 29, which prevent the amyloid fibril formation that makes native amylin unsuitable as a therapeutic agent.

Mechanism of Action#

Pramlintide mimics the actions of native amylin through three primary mechanisms:

• Gastric emptying delay: Slows the rate at which food leaves the stomach, reducing the rate of glucose appearance in the bloodstream after meals
• Glucagon suppression: Inhibits inappropriate postprandial glucagon secretion, reducing hepatic glucose output after meals
• Satiety promotion: Activates central satiety pathways in the brain, reducing food intake and contributing to weight neutrality or modest weight loss

These effects are complementary to insulin and specifically address the postprandial glucose excursions that are difficult to control with insulin alone.

Research Overview#

Pramlintide was evaluated in extensive phase 3 clinical trials in both type 1 and type 2 diabetes populations. Key studies demonstrated HbA1c reduction of approximately 0.5-0.7% when added to insulin, accompanied by modest weight loss rather than the weight gain typically associated with insulin intensification.

Important Considerations#

• Must be administered as a separate injection from insulin; cannot be mixed
• Carries an FDA boxed warning for insulin-induced severe hypoglycemia
• Mealtime insulin dose must be reduced by 50% when starting pramlintide
• Very short half-life (~48 minutes) requires injection before each meal
• Available as a multidose pen (SymlinPen) for subcutaneous injection
• Most commonly prescribed in type 1 diabetes where postprandial control is challenging

Key Research Findings#

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial, published in Diabetes Care (Hollander PA et al., 2003; PMID: 12610038):

• The study showed HbA1c reduction with pramlintide 120 mcg BID of 0.62% at 52 weeks vs placebo
• The study showed weight change of 1.4 kg with pramlintide vs +0.7 kg with placebo at 52 weeks

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes, published in Diabetes Care (Whitehouse F et al., 2002; PMID: 11919132):

• The study showed HbA1c reduction of 0.67% at 13 weeks vs -0.16% with placebo (significant treatment difference)

Related Reading#

• Pramlintide (Symlin) research studies and evidence
• Pramlintide (Symlin) dosing protocols
• Pramlintide (Symlin) side effects profile
• Cagrilintide research guide
• GUBamy research guide